SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-20-050915
Filing Date
2020-11-05
Accepted
2020-11-05 09:01:01
Documents
62
Period of Report
2020-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q ntla-10q_20200930.htm   iXBRL 10-Q 2917881
2 EX-31.1 ntla-ex311_6.htm EX-31.1 17027
3 EX-31.2 ntla-ex312_8.htm EX-31.2 17043
4 EX-32.1 ntla-ex321_9.htm EX-32.1 6276
  Complete submission text file 0001564590-20-050915.txt   10866902

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA ntla-20200930.xsd EX-101.SCH 51347
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE ntla-20200930_cal.xml EX-101.CAL 32665
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE ntla-20200930_def.xml EX-101.DEF 183284
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE ntla-20200930_lab.xml EX-101.LAB 400281
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ntla-20200930_pre.xml EX-101.PRE 307727
10 EXTRACTED XBRL INSTANCE DOCUMENT ntla-10q_20200930_htm.xml XML 2642381
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

IRS No.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37766 | Film No.: 201288997
SIC: 2835 In Vitro & In Vivo Diagnostic Substances